Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Open-Label, Multicenter Study of VELCADE With Rituximab or Rituximab Alone in Subjects With Relapsed or Refractory, Rituximab Naive or Sensitive Follicular B-Cell Non-Hodgkin's Lymphoma.

Next Previous
X
Search
Trial Profile

A Randomized, Open-Label, Multicenter Study of VELCADE With Rituximab or Rituximab Alone in Subjects With Relapsed or Refractory, Rituximab Naive or Sensitive Follicular B-Cell Non-Hodgkin's Lymphoma.

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 08 Oct 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Bortezomib (Primary) ; Rituximab
  • Indications Follicular lymphoma
  • Focus Registrational; Therapeutic Use
  • Sponsors Janssen-Cilag

    • Most Recent Events

    • 09 Dec 2011 Results will be presented at the 53rd Annual Meeting and Exposition of the American Society of Hematology, according to a Janssen-Cilag media release.
    • 12 Jun 2011 Patient-reported quality-of-life outcomes presented at the 16th Congress of the European Hematology Association.
    • 12 Jun 2011 Primary endpoint 'Progression-free-survival-duration' has been met.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top